Results 131 to 140 of about 11,407 (210)

Rapid detection of ceftazidime/avibactam resistance by MALDI-TOF MS [PDF]

Journal of Antimicrobial Chemotherapy, 2018
Cecilia Godoy, Carvalhaes, Ana Carolina, Ramos, Lilian Caroline Gonçalves de, Oliveira, Maria Aparecida, Juliano, Ana Cristina, Gales   +4 more
openaire   +2 more sources

Ceftazidime–Avibactam Pharmacokinetic Comparative In Vivo/In Vitro Study in a Critically Ill Children Under High‐Volume Continuous Venovenous Hemodiafiltration

Pharmacology Research & Perspectives
Ceftazidime–avibactam is a novel cephalosporin/beta‐lactamase inhibitor combination developed to address increasing antimicrobial resistance. This report presents a comparative study of the pharmacokinetics of ceftazidime and avibactam, utilizing in ...
Michael Thy, Alexandre Debs, Gabrielle Lui, Leo Froelicher‐Bournaud, Jean‐Marc Tréluyer, Mehdi Oualha   +5 more
doaj   +1 more source

Correction to “Persistent Burkholderia cepacia Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co‐Trimoxazole With Risk of Infective Endocarditis—A Case Report”

Clinical Case Reports, Volume 14, Issue 2, February 2026.
wiley   +1 more source

In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii

Journal of Global Antimicrobial Resistance
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a global concern as effective treatments are very limited. We previously used a modified susceptibility testing approach to predict growth suppression in carbapenem-resistant Enterobacterales, but there are uncertainties about the generalizability of the model.
Nazanin Pouya, James E. Smith, Cole S. Hudson, Nicholas S. Teran, Vincent H. Tam   +4 more
openaire   +3 more sources

The bacterial etiology and antimicrobial susceptibility of lower respiratory tract infections in Vietnam

Annals of Clinical Microbiology and Antimicrobials
Background Lower respiratory tract infection (LRTI) remains the leading infectious cause of morbidity and mortality globally. Key bacterial pathogens include Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli ...
Tran Thi Ngoc Dung, Chau Vinh, Pham Hong Anh, Vo Kim Phuong Linh, Ha Thanh Tuyen, Pham Thanh Tam, Nguyen Phu Huong Lan, Truong Thien Phu, Nguyen Su Minh Tuyet, Pham Hong Nhung, Van Dinh Trang, Nguyen Thi Van, Quynh Nguyen, Nguyen Thi Thanh, Thomas Kesteman, H. Rogier van Doorn, Guy Thwaites, Pham Thanh Duy   +17 more
doaj   +1 more source

Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Organisms: A Prospective, Observational, Single-Center Study

Antibiotics
Introduction: The World Health Organization has declared carbapenem-resistant organisms a research and development priority. Although ceftazidime–avibactam was approved around a decade ago, there is still a lack of prospective data on the treatment of ...
Frieder Pfäfflin, Anja Theloe, Miriam Songa Stegemann, Rasmus Leistner, Leif Erik Sander, Florian Kurth, Stephan Achterberg   +6 more
doaj   +1 more source

Iowa Board of Pharmacy News, March 2016 [PDF]

, 2016
The Iowa Board of Pharmacy News is published by the Iowa Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote compliance of pharmacy and drug ...

core  

Интраабдоминальная инфекция в свете последних международных рекомендаций и ее роль в развитии септической энцефалопатии [PDF]

, 2018
Цель данных рекомендаций: представить международную позицию, основанную на доказательствах, по вопросам тактики ведения интраабдоминальных инфекций и влияние интраабдоминальных инфекций на развитие септической энцефалопатии.
Лисничая, В.Н., Мальцева, Л.А., Мосенцев, Н.Ф.   +2 more
core  

Multidrug-resistant Pseudomonas aeruginosa from sputum of patients with cystic fibrosis demonstrates a high rate of susceptibility to ceftazidime–avibactam

Infection and Drug Resistance, 2018
Stan D Atkin,1 Shadaan Abid,1 Michael Foster,1 Moumita Bose,1 Ashley Keller,1 Rita Hollaway,2 Helio S Sader,3 David E Greenberg,1,4 James D Finklea,1 Mariana Castanheira,3 Raksha Jain1,4 1Department of Internal Medicine, University of Texas Southwestern ...
Atkin SD, Abid S, Foster M, Bose M, Keller A, Hollaway R, Sader HS, Greenberg DE, Finklea JD, Castanheira M, Jain R   +10 more
doaj  

Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance. [PDF]

Antimicrob Agents Chemother
Myers CL, Stevenson A, Miller B, Daigle DM, Uehara T, Pevear DC.   +5 more
europepmc   +2 more sources